Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The tumor doubling time is a useful parameter for predicting the histological type of thymic epithelial tumors.

Fukumoto K, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Mori S, Goto M, Hashimoto K, Tateyama H, Yokoi K.

Surg Today. 2019 May 27. doi: 10.1007/s00595-019-01822-9. [Epub ahead of print]

PMID:
31134370
2.

The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.

Fukumoto K, Taniguchi T, Ishikawa Y, Kawaguchi K, Fukui T, Kato K, Matsuo K, Yokoi K.

Eur J Cardiothorac Surg. 2012 Dec;42(6):e152-6. doi: 10.1093/ejcts/ezs527. Epub 2012 Sep 28.

PMID:
23024234
3.

Doubling time of thymic epithelial tumours on CT: correlation with histological subtype.

Choe J, Lee SM, Lim S, Choi SH, Kim N, Do KH, Seo JB.

Eur Radiol. 2017 Oct;27(10):4030-4036. doi: 10.1007/s00330-017-4795-y. Epub 2017 Mar 22.

PMID:
28332015
4.

Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors.

Endo M, Nakagawa K, Ohde Y, Okumura T, Kondo H, Igawa S, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Yamamoto N, Ito I, Kameya T.

Lung Cancer. 2008 Sep;61(3):350-5. doi: 10.1016/j.lungcan.2008.01.003. Epub 2008 Mar 4.

PMID:
18304691
5.

Can 18F-FDG PET predict the grade of malignancy in thymic epithelial tumors? An evaluation of only resected tumors.

Nakagawa K, Takahashi S, Endo M, Ohde Y, Kurihara H, Terauchi T.

Cancer Manag Res. 2017 Dec 5;9:761-768. doi: 10.2147/CMAR.S146522. eCollection 2017.

6.

Usefulness of [18F]fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors.

Igai H, Matsuura N, Tarumi S, Chang SS, Misaki N, Go T, Ishikawa S, Yokomise H.

Eur J Cardiothorac Surg. 2011 Jul;40(1):143-5. doi: 10.1016/j.ejcts.2010.09.009. Epub 2010 Oct 15.

PMID:
20951602
7.

Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.

Du MJ, Shen Q, Yin H, Rao Q, Zhou MX.

Pathol Res Pract. 2016 Nov;212(11):1048-1051. doi: 10.1016/j.prp.2016.09.005. Epub 2016 Sep 13.

PMID:
27688088
8.

¹⁸F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival.

Seki N, Sakamoto S, Karube Y, Oyaizu T, Ishihama H, Chida M.

Ann Nucl Med. 2014 Apr;28(3):257-62. doi: 10.1007/s12149-014-0804-2. Epub 2014 Jan 16.

PMID:
24430867
9.

[Correlation of amplification of chromosome 1 with histologic typing of thymic epithelial tumors].

Ma YQ, Zhang C, Cui WL, Gulinaer A, Zhang W, Wang J.

Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):820-4. Chinese.

PMID:
22336207
10.

[Clinicopathologic analysis of 52 cases of thymic epithelial tumor].

Ma YQ, Miao N, Abulajiang G, Li QX, Liu X, Zhang W, Wang CF, Wang J.

Zhonghua Bing Li Xue Za Zhi. 2010 Apr;39(4):249-54. Chinese.

PMID:
20654124
11.

Utility of 18F-fluorodeoxyglucose positron emission tomography for distinguishing between the histological types of early stage thymic epithelial tumours.

Eguchi T, Yoshida K, Hamanaka K, Shiina T, Koizumi T, Kawakami S, Oguchi K, Amano J.

Eur J Cardiothorac Surg. 2012 May;41(5):1059-62. doi: 10.1093/ejcts/ezr144. Epub 2011 Dec 21.

PMID:
22219437
12.

Diagnostic reproducibility of thymic epithelial tumors using the World Health Organization classification: note for thoracic clinicians.

Sakakura N, Tateyama H, Nakamura S, Taniguchi T, Usami N, Ishikawa Y, Kawaguchi K, Yokoi K.

Gen Thorac Cardiovasc Surg. 2013 Feb;61(2):89-95. doi: 10.1007/s11748-012-0187-z. Epub 2012 Dec 12.

PMID:
23229995
13.

Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis?

Jeong YJ, Lee KS, Kim J, Shim YM, Han J, Kwon OJ.

AJR Am J Roentgenol. 2004 Aug;183(2):283-9.

PMID:
15269013
14.

Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.

Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A.

Mod Pathol. 2009 Oct;22(10):1341-50. doi: 10.1038/modpathol.2009.105. Epub 2009 Jul 31.

15.

Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis.

Lococo F, Cesario A, Okami J, Cardillo G, Cavuto S, Tokunaga T, Apolone G, Margaritora S, Granone P.

Lung Cancer. 2013 Nov;82(2):245-51. doi: 10.1016/j.lungcan.2013.08.003. Epub 2013 Aug 13.

PMID:
23992878
16.

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center.

Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T.

BMC Cancer. 2014 May 20;14:349. doi: 10.1186/1471-2407-14-349.

17.

JOURNAL CLUB: Doubling Time of Thymic Epithelial Tumors Correlates With World Health Organization Histopathologic Classification.

Jeong DY, Lee KS, Chung MJ, Zo JI, Shim YM, Moon JW.

AJR Am J Roentgenol. 2017 Oct;209(4):W202-W210. doi: 10.2214/AJR.17.17836. Epub 2017 Aug 10.

PMID:
28796544
18.

18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.

Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA.

J Nucl Med. 2006 Oct;47(10):1628-34.

19.

Analysis of surgical treatment of Masaoka stage III-IV thymic epithelial tumors.

Hamanaka K, Koyama T, Matsuoka S, Takeda T, Miura K, Yamada K, Hyogotani A, Seto T, Okada K, Ito KI.

Gen Thorac Cardiovasc Surg. 2018 Dec;66(12):731-735. doi: 10.1007/s11748-018-0996-9. Epub 2018 Aug 21.

PMID:
30132223
20.

Type B3 thymoma with marked neuroendocrine differentiation: Report of a case.

Sato K, Fumimoto S, Kataoka T, Ichihashi Y, Ochi K, Satomi H, Hanaoka N, Okada Y, Katsumata T.

SAGE Open Med Case Rep. 2019 Feb 1;7:2050313X19827749. doi: 10.1177/2050313X19827749. eCollection 2019.

Supplemental Content

Support Center